Prosecution Insights
Prosecution Insights
33 pending office actions • 8 clients • 30 examiners • 22 art units • 0 of 33 (0%) have an AI response strategy ready • 45 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 33 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 33 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 15 (45%) |
| §112 only | 4 (12%) |
| Double-patenting + other | 1 (3%) |
| No statute on record | 13 (39%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 3 | 77.6% | +20.3% |
| HADDAD, MAHER M | 2 | 50.4% | +54.3% |
| ROONEY, NORA MAUREEN | 1 | 60.5% | +23.2% |
| WEN, SHARON X | 1 | 56.5% | +32.8% |
| HOLLAND, PAUL J | 1 | 57.5% | +64.7% |
| SHOMER, ISAAC | 1 | 63.1% | +30.7% |
| BEANE, RANDALL L | 1 | 32.5% | +37.8% |
| PETERS, ALEC JON | 1 | 68.6% | +61.7% |
| O'BRIEN, LEA S | 1 | 50.0% | +8.3% |
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18296283 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | BRETZ, COREY LANE | 56d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17727309 | ANTI-ICOS ANTIBODIES | OUSPENSKI, ILIA I | 204d overdue |
| 18512687 | METHODS, CELLS & ORGANISMS | HOLLAND, PAUL J | 140d overdue |
| 18592425 | ANTI-PD-L1 AND IL-2 CYTOKINES | ROONEY, NORA MAUREEN | 42d overdue |
| 18358601 | THROMBIN CLEAVABLE LINKER WITH XTEN AND ITS USES THEREOF | BEANE, RANDALL L | 37d overdue |
| 18364906 | ANTIBODIES, USES & METHODS | HADDAD, MAHER M | 7d |
| 18555439 | "Good" buffer-based cationic lipids | SHOMER, ISAAC | 9d |
| 17725228 | SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD | OUSPENSKI, ILIA I | 12d |
| 18324668 | ANTI-BCMA ANTIBODIES | PETERS, ALEC JON | 16d |
| Client (Assignee) | Pending OAs |
|---|---|
| KYMAB LIMITED | 7 |
| TRANSLATE BIO, INC. | 7 |
| Regeneron | 5 |
| Bioverativ Therapeutics | 4 |
| Sanofi | 4 |
| GENZYME CORPORATION | 4 |
| Sanofi Aatd Inc. | 1 |
| miRecule | 1 |
| Art Unit | Apps |
|---|---|
| 1641 | 5 |
| 1635 | 3 |
| 1644 | 3 |
| 1654 | 2 |
| 1643 | 2 |
| 1637 | 2 |
| 1656 | 1 |
| 1612 | 1 |
| 1646 | 1 |
| 1674 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18592425 | ANTI-PD-L1 AND IL-2 CYTOKINES | Kymab Limited | ROONEY, NORA MAUREEN | 1641 | §103 | Non-Final OA | 42d overdue | Pending | Feb 29, 2024 |
| 18407331 | METHODS FOR REDUCING OR ELIMINATING THE NEED FOR LIPOPROTEIN APHERESIS IN PATIENTS WITH HYPERLIPIDEMIA BY ADMINISTERING ALIROCUMAB | Regeneron Pharmaceuticals, Inc. | WEN, SHARON X | 1641 | Other | Non-Final OA | 30d | Pending | Jan 08, 2024 |
| 18512687 | METHODS, CELLS & ORGANISMS | Kymab Limited | HOLLAND, PAUL J | 1656 | Other | Final Rejection | 140d overdue | Pending | Nov 17, 2023 |
| 18555439 | "Good" buffer-based cationic lipids | Translate Bio, Inc. | SHOMER, ISAAC | 1612 | Other | Final Rejection | 9d | Pending | Oct 13, 2023 |
| 18459995 | ANTIBODIES, COMBINATIONS COMPRISING ANTIBODIES, BIOMARKERS, USES & METHODS | Kymab Limited | HADDAD, MAHER M | 1641 | §103 | Final Rejection | 26d | Pending | Sep 01, 2023 |
| 18364906 | ANTIBODIES, USES & METHODS | Kymab Limited | HADDAD, MAHER M | 1641 | Other | Final Rejection | 7d | Pending | Aug 03, 2023 |
| 18358601 | THROMBIN CLEAVABLE LINKER WITH XTEN AND ITS USES THEREOF | BIOVERATIV THERAPEUTICS INC. | BEANE, RANDALL L | 1654 | §103 | Final Rejection | 37d overdue | Pending | Jul 25, 2023 |
| 18324668 | ANTI-BCMA ANTIBODIES | Sanofi | PETERS, ALEC JON | 1641 | Other | Non-Final OA | 16d | Pending | May 26, 2023 |
| 18318425 | EFFECTIVE DOSAGE OF RECOMBINANT SERPIN-FC FUSION PROTEIN FOR USE IN A METHOD OF TREATING AAT DEFICIENCY IN A SUBJECT | Sanofi Aatd Inc. | O'BRIEN, LEA S | 1646 | §103 | Non-Final OA | 54d | Pending | May 16, 2023 |
| 18296283 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | Genzyme Corporation | BRETZ, COREY LANE | 1635 | Other | Non-Final OA | 56d | Pending | Apr 05, 2023 |
| 18130980 | COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST | Regeneron Pharmaceuticals, Inc. | HOWARD, ZACHARY C | 1674 | §103 | Non-Final OA | 127d overdue | Pending | Apr 05, 2023 |
| 18246263 | PIPERAZINE-BASED CATIONIC LIPIDS | Translate Bio, Inc. | ANDERSON, REBECCA L | 1626 | Other | Non-Final OA | 18d overdue | Pending | Mar 22, 2023 |
| 17969033 | METHODS FOR TREATING PRURIGO NODULARIS BY ADMINISTERING AN IL-4R ANTAGONIST | Regeneron Pharmaceuticals, Inc. | NATARAJAN, MEERA | 1643 | §103 | Final Rejection | 4d overdue | Pending | Mar 02, 2023 |
| 18174925 | BISPECIFIC ANTIBODY FOR ICOS AND PD-L1 | Kymab Limited | OUSPENSKI, ILIA I | 1644 | DPOther | Final Rejection | 63d | Pending | Feb 27, 2023 |
| 18016625 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | Sanofi Pasteur | ROZOF, TIMOTHY R | 1625 | §112 | Non-Final OA | 6d | Pending | Jan 17, 2023 |
| 18045995 | FGFR3 ANTIBODIES AND METHODS OF USE | Genzyme Corporation | ALLEN, MARIANNE P | 1647 | §112 | Non-Final OA | 26d | Pending | Oct 12, 2022 |
| 17915215 | Targeted Inhibition Using Engineered Oligonucleotides | Mirecule, Inc. | MCKILLOP, JOHN CHARLES | 1637 | Other | Non-Final OA | 8d overdue | Pending | Sep 28, 2022 |
| 17801099 | PROPIONIBACTERIUM ACNES PROPHYLACTIC AND THERAPEUTIC IMMUNE TREATMENT | Sanofi Pasteur Inc. | GRASER, JENNIFER E | 1645 | §112 | Final Rejection | 70d | Pending | Aug 19, 2022 |
| 17872225 | METHODS FOR TREATING CHRONIC SPONTANEOUS URTICARIA BY ADMINISTERING AN IL-4R ANTAGONIST | Regeneron Pharmaceuticals, Inc. | PATTERSON, SARAH COOPER | 1675 | Other | Final Rejection | 30d | Pending | Jul 25, 2022 |
| 17843445 | MULTIVALENT INFLUENZA VACCINES | Sanofi Pasteur Inc. | HILL, MYRON G | 1671 | Other | Final Rejection | 17d overdue | Pending | Jun 17, 2022 |
| 17775446 | BIPARATOPIC CD73 ANTIBODIES | Genzyme Corporation | AEDER, SEAN E | 1642 | §103 | Final Rejection | 22d | Pending | May 09, 2022 |
| 17727309 | ANTI-ICOS ANTIBODIES | Kymab Limited | OUSPENSKI, ILIA I | 1644 | Other | Non-Final OA | 204d overdue | Pending | Apr 22, 2022 |
| 17725228 | SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD | Kymab Limited | OUSPENSKI, ILIA I | 1644 | Other | Non-Final OA | 12d | Pending | Apr 20, 2022 |
| 17592335 | MRNA THERAPY FOR THE TREATMENT OF OCULAR DISEASES | Translate Bio, Inc. | NGUYEN, QUANG | 1631 | §103 | Non-Final OA | 238d overdue | Pending | Feb 03, 2022 |
| 17576562 | ENGINEERED ITR SEQUENCES AND METHODS OF USE | BIOVERATIV THERAPEUTICS INC. | SHUKLA, RAM R | 1635 | Other | Non-Final OA | 2d overdue | Pending | Jan 14, 2022 |
| 17576561 | BACULOVIRUS EXPRESSION SYSTEM | BIOVERATIV THERAPEUTICS INC. | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103 | Final Rejection | 52d overdue | Pending | Jan 14, 2022 |
| 17450629 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | Translate Bio, Inc. | POPA, ILEANA | 1633 | §103 | Final Rejection | 9d | Pending | Oct 12, 2021 |
| 17403592 | GLYCOENGINEERED ANTIBODY DRUG CONJUGATES | Genzyme Corporation | LEE, HOI YAN NMN | 1693 | §103 | Final Rejection | 21d | Pending | Aug 16, 2021 |
| 17291937 | 2,5-DIOXOPIPERAZINE LIPIDS WITH INTERCALATED ESTER, THIOESTER, DISULFIDE AND ANHYDRIDE MOIEITIES | Translate Bio, Inc. | AUDET, MAURY A | 1654 | §112 | Non-Final OA | 79d | Pending | May 06, 2021 |
| 17183904 | COMPOSITIONS COMPRISING IL6R ANTIBODIES FOR THE TREATMENT OF UVEITIS AND MACULAR EDEMA AND METHODS OF USING SAME | Regeneron Pharmaceuticals, Inc. | FAUST, AMBER KATHLEEN | 1643 | §103 | Non-Final OA | 33d | Pending | Feb 24, 2021 |
| 17172527 | METHODS AND COMPOSITIONS FOR MESSENGER RNA PURIFICATION | Translate Bio, Inc. | POHNERT, STEVEN C | 1683 | §103 | Non-Final OA | 96d overdue | Pending | Feb 10, 2021 |
| 17076195 | COMPOSITIONS, METHODS AND USES OF MESSENGER RNA | Translate Bio, Inc. | SHIN, DANA H | 1635 | §103 | Final Rejection | 71d overdue | Pending | Oct 21, 2020 |
| 16965895 | USE OF LENTIVIRAL VECTORS EXPRESSING FACTOR VIII | BIOVERATIV THERAPEUTICS INC. | MARVICH, MARIA | 1634 | §103 | Final Rejection | 24d overdue | Pending | Jul 29, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial